CDK4 and neoplasm: Patient EOC1067 progressed after 9 months of platinum-based therapy despite the FANCA deletion conferring HR deficiency, potentially because of the contribution of the CDK alterations on cell-cycle regulation and tumor progression.32 On the basis of the concurrent CKDN1B and CKDN2B deletions, this patient could potentially benefit from a combination targeting both pathways, for instance, PARP inhibitor and CDK4/6 inhibitor.